Countering High Telomerase Activity

Why It Matters

"Most cancers express the enzyme telomerase that restabilizes the telomeres and allows unlimited cell division potential (immortalization); thus telomerase represents an attractive therapeutic target." — Campbell Walsh Wein Urology

Strategies to Counter High Telomerase Activity

1. Direct Telomerase Enzyme Inhibitors (Small Molecules)

2. Antisense Oligonucleotides (ASOs) / RNA Interference (RNAi)

• ASOs complementary to hTR block the RNA template component → no template, no telomere synthesis
• siRNA/shRNA targeting hTERT or hTR delivered via adenoviral vectors → abrogates telomerase activity → marked inhibition of tumor cell growth in xenograft models
• Demonstrated in oral squamous cell carcinoma (SCC): adenovirus-delivered siRNA against both hTR and hTERT produced "measurable decline in telomerase activity" and significant growth inhibition — Cummings Otolaryngology

3. G-Quadruplex (G4) Stabilizers

• TMPyP4 (a porphyrin) — binds and stabilizes G4 structures
• Telomestatin — highly potent, derived from Streptomyces anulatus; one of the most selective G4 stabilizers known
• Multiple G4 ligands are in active development

4. Telomerase-Targeted Immunotherapy

• Therapeutic DNA vaccines encoding modified hTERT → host immune system generates cytotoxic T-lymphocytes (CTLs) against telomerase-expressing cells → selective cancer cell killing
  • Vaccines by Invectys and Inovio were well-tolerated in clinical trials
• Peptide-based vaccines and dendritic cell vaccines presenting hTERT peptides
• Cell-based immunotherapy (CAR-T approaches targeting hTERT-expressing cells) — emerging

5. Gene Therapy / Oncolytic Viruses

• Suicide gene therapy: TERT promoter-driven expression of a suicide gene (e.g., thymidine kinase) — only active in telomerase-expressing cancer cells → selective killing upon prodrug administration
• Oncolytic viruses engineered so that replication is controlled by the TERT promoter → virus replicates only in telomerase-positive (cancer) cells, lysing them

6. Targeting the ALT Pathway (Alternative Lengthening of Telomeres)

• Inhibitors of ATRX/DAXX chromatin remodeling
• Targeting RAD51 recombinase
• Exploiting synthetic lethality in ALT-positive cells

7. Indirect Approaches: Upstream Regulation of hTERT Expression

8. Natural Compounds with Telomerase-Inhibitory Activity

• Genistein (soy isoflavone) — inhibits Akt → dephosphorylates hTERT → reduced telomerase activity in prostate cancer cells
• Curcumin — downregulates hTERT expression via NF-κB and Wnt/β-catenin pathways
• Epigallocatechin gallate (EGCG) — G4 stabilization and hTERT repression
• Resveratrol — reduces hTERT transcription

Key Limitation: Stem Cell Toxicity

"Any such inhibitor could also adversely affect normal stem cells... This is a major limitation to such an approach." — Harper's Illustrated Biochemistry, 32nd Ed

The "Lag Effect" Problem

Clinical Summary

Stoma Operation

What Is a Stoma?

Why Is a Stoma Created?

• Colorectal cancer — to divert waste away from a surgical anastomosis (join) or after removal of the rectum
• Inflammatory bowel disease (IBD) — Crohn's disease, ulcerative colitis
• Bowel obstruction — e.g., obstructing rectal cancer
• Trauma or injury to the bowel
• Diverticular disease complications (perforation, Hartmann's procedure)
• Incontinence — severe or unmanageable
• Protecting an anastomosis — allowing a newly joined bowel segment to heal without fecal contamination
• Neurological conditions — spinal injury, paraplegia
• Bladder cancer or bladder removal (cystectomy) — for urinary diversion

Types of Stoma

By Origin of Bowel

By Configuration

• Loop ileostomy: preferred for protecting a low rectal anastomosis or ileal pouch. Easy to bring to the surface; produces less odor than a loop colostomy; easier to close.
• Loop colostomy (transverse): seldom recommended now due to high risk of prolapse and poor appliance adherence from its location near the beltline.

By Duration

Surgical Construction

Ileostomy

• Brooke spouted ileostomy: the ileum is everted and sutured to create a spout projecting 2–4 cm above the skin surface — essential to protect the skin from liquid effluent
• Brought through the rectus abdominis muscle, right iliac fossa
• A disposable appliance (drainable bag, left in place ~48 hours) is applied

Colostomy

• Generally flush with the skin or slightly everted (0.5–1 cm projection)
• Aperture in abdominal wall should admit two fingers; muscle-splitting technique through the rectus
• Descending/sigmoid colostomies are preferred over transverse because most of the colon remains in circuit → more water absorption → more formed stool
• Ascending colostomies produce more liquid effluent

Stoma Siting (Pre-operative Marking)

• Lie within the rectus abdominis muscle (reduces hernia risk)
• Be visible to the patient when standing, sitting, and bending
• Avoid skin folds, bony prominences, scars, belt lines, and the umbilicus

Stoma Appliances

• Ileostomy: drainable bags, changed every 48 hours
• Colostomy: closed bags, changed 2–3 times daily
• Modern appliances incorporate an adhesive backing that can remain in place for several days
• A stoma care nurse specialist is essential for advice, appliance selection, and psychological support

Complications

Early

Late

Reversal (Stoma Takedown)

Psychological and Quality-of-Life Considerations

Lower Back Disc Pain and Women: A Nuanced Picture

First, an Important Clarification

• Acute disc herniation (disc prolapse/rupture) — actually more common in men, particularly ages 30–50
• Chronic low back pain (LBP) overall — female sex is an established risk factor
• Disc degeneration by imaging — high prevalence in both sexes by middle age, with women showing substantial rates detected incidentally

"Risk factors for chronic LBP include female sex, African-American race, older age, being unemployed, obesity, and sedentary lifestyle." — Harrison's Principles of Internal Medicine 22E (2025)

"Symptomatic lumbar disc herniation... Risk factors include family history, male gender, age (30–50 years), heavy lifting or twisting, stressful occupation, lower income and cigarette smoking." — Bailey and Love's Short Practice of Surgery, 28th Ed

Reasons Why Women Experience More Chronic LBP and Disc-Related Pain

1. Anatomical Differences

"The normal spine shows thoracic kyphosis and lumbar lordosis in the sagittal plane, which in some individuals may be exaggerated. In the coronal plane, the spine is normally straight or shows a slight curvature, particularly in women." — Adams and Victor's Principles of Neurology, 12th Ed

2. Hormonal Factors

"Among women who had MRI for gynecologic reasons, the frequency of lumbar disc degeneration and bulging approaching 70 percent by age 50 (Powell and coworkers)." — Adams and Victor's Principles of Neurology, 12th Ed

"Osteoporosis, especially in older women, is a further important cause of vertebral flattening or collapse, additionally narrowing the spinal canal." — Adams and Victor's Principles of Neurology, 12th Ed

3. Pregnancy-Related Changes

"Low back pain is ubiquitous in the nongravid female population and increases during pregnancy... As many as three-quarters of pregnant women report low back pain at some time in their pregnancy." — Bradley and Daroff's Neurology in Clinical Practice

• Increasing lumbar lordosis as the uterus enlarges and shifts the center of gravity anteriorly
• Direct pressure from the enlarging uterus on lumbar structures
• Hormonally induced ligamentous laxity (relaxin, progesterone)
• Postural stress and altered gait mechanics
• Weight gain increasing axial load on discs

4. Pain Processing and Sensitization Differences

• Women have a lower pain threshold and higher pain ratings for equivalent stimuli in experimental settings
• Women are more susceptible to nociplastic (central sensitization) pain, which is pain arising from abnormal central processing without proportionate tissue damage — a major driver of chronic LBP
• Higher rates of co-existing conditions (fibromyalgia, depression, anxiety) that amplify pain perception

"Nocipastic back pain... is characterized by diffuse pain, superficial tenderness, and pain patterns that deviate from normal neuroanatomy... generally co-prevalent with other nocipplastic conditions." — Harrison's Principles of Internal Medicine 22E (2025)

5. Occupational and Behavioral Factors

• Women are disproportionately represented in occupations involving prolonged sedentary posture (administrative work) and repetitive bending/lifting (caregiving, nursing), both risk factors for LBP
• Women are less likely to have high paraspinal muscle mass, which acts as a natural stabilizer and protector of the lumbar spine
• Women report higher disability from back pain and are more likely to seek healthcare, which may partly explain apparent prevalence differences

6. Disc Degeneration Accelerates Post-Menopause

• Accelerated loss of disc hydration
• Reduction of disc height
• Increased annular fissuring
• Earlier onset of radiculopathy from foraminal narrowing

Summary Table

Disc Degeneration Accelerating After Menopause

Overview

"IVD degeneration and facet joint osteoarthritis are two common causes of LBP, and both occur more frequently in elderly women than in other populations. Moreover, osteoarthritis and OA pain, regardless of the joint, are experienced by up to twice as many women as men, and this difference is amplified during menopause." — Pang et al., Bone Research, 2023 (PMID 37542028)

Normal Disc Structure (Baseline)

"With normal ageing, the water content [of the nucleus pulposus] decreases." — Grainger & Allison's Diagnostic Radiology

"With time, the nucleus pulposus undergoes loss of proteoglycans and water (desiccation)... Early degenerative disc disease is an irreversible process, with IL-1β stimulating the release of MMPs, nitric oxide, IL-6, and prostaglandin E2." — Miller's Review of Orthopaedics, 9th Ed

How Estrogen Protects the Disc

1. Proteoglycan Synthesis and Water Retention

• Proteoglycan production falls
• Aggrecan molecules break down faster than they are replaced
• The nucleus pulposus loses water content (desiccation)
• Disc height decreases
• The disc becomes stiffer and less able to distribute compressive loads

"Deposition of collagen and elastin and alterations of glycosaminoglycans combine to decrease the water content of the nucleus pulposus; concomitantly, the cartilaginous endplate becomes less vascular." — Adams and Victor's Principles of Neurology, 12th Ed

2. Anti-inflammatory Effects

• IL-1β and TNF-α activity increases in disc and facet joint tissue
• MMPs degrade type II collagen and aggrecan faster
• The anabolic-catabolic balance of the disc shifts toward breakdown
• Inflammatory sensitization of nociceptors within the outer annulus causes pain

3. Collagen Quality and Annular Integrity

4. Endplate Vascularization

"Concomitantly, the cartilaginous endplate becomes less vascular... aging: calcification impairs diffusion [of nutrients into the disc]." — Adams and Victor's Principles of Neurology / Miller's Review of Orthopaedics

5. Disc Cell Survival

Compounding Factor: Post-Menopausal Osteoporosis

• Vertebral compression fractures (especially T12–L2)
• Vertebral height loss → altered disc mechanics and additional stress on adjacent discs
• Spinal canal narrowing → disc and nerve root compression
• Cascading degeneration of adjacent spinal segments

"Osteoporotic vertebral compression fractures occur most commonly in the thoracic and thoracolumbar spine, especially in postmenopausal women. By age 75 years, nearly a fourth of women have vertebral compression fractures." — Bradley and Daroff's Neurology in Clinical Practice

"Osteoporosis, especially in older women, is a further important cause of vertebral flattening or collapse, additionally narrowing the spinal canal." — Adams and Victor's Principles of Neurology, 12th Ed

The Combined Timeline

Clinical Consequences

1. Disc space narrowing on X-ray / MRI — reduced disc height visible from 50s onward
2. Modic changes — inflammatory endplate signal changes, strongly associated with pain
3. Radiculopathy — disc bulge or herniation compressing nerve roots (leg pain, sciatica)
4. Degenerative spinal stenosis — narrowing of the spinal canal from bulging discs + facet hypertrophy + ligamentum flavum thickening
5. Facet joint osteoarthritis — co-degeneration with discs, amplified by estrogen deficiency
6. Vertebral compression fractures from osteoporosis — acute back pain, height loss, kyphosis

Therapeutic Implications

"Estrogen supplementation has been shown to be effective at ameliorating IVD degeneration and OA progression, indicating its potential use as a therapeutic agent for people with LBP and OA pain." — Pang et al., Bone Research, 2023

Professional Histopathology Report Interpretation

Patient: Revabhai Koyabhai Patel | Male, 76 Years | Reg. No: 605101320

Complete Core-by-Core Summary

Key Pathological Findings

1. Prostatic Acinar Adenocarcinoma — Confirmed in 2 of 12 Cores (Bilateral)

• Gleason Score: 3 + 3 = 6
• Grade Group: 1 (lowest possible grade)
• Perineural invasion: Not evident (favorable)
• Tumor volume: ~40% of submitted core

• Gleason Score: 3 + 3 = 6
• Grade Group: 1
• Perineural invasion: Not evident (favorable)
• Tumor volume: ~20% of submitted core

2. Atypical Small Acinar Proliferation (ASAP) — Present in 4 of 12 Cores

"Atypical small acinar proliferation is observed in approximately 5% of prostate biopsies, and between 30 to 50% of individuals with this finding will have invasive cancer on repeat biopsy." — Goldman-Cecil Medicine

"Atypical small acinar proliferation (ASAP) on initial biopsy... 40% cancer risk [on repeat biopsy]." — Campbell Walsh Wein Urology

3. Chronic Prostatitis (Core 6, RL2)

Risk Stratification (NCCN Criteria)

• Gleason score ≤6, Grade Group 1 → Low-risk or Very Low-risk by NCCN criteria
• To classify as Very Low Risk, additional criteria must be met: T1c, PSA <10 ng/mL, fewer than 3 positive cores with ≤50% involvement, PSA density <0.15 ng/mL/g

Clinical Significance by Finding

Grade Group 1 (Gleason 3+3=6) — What It Means

• Composed entirely of well-formed, individual glands — the most indolent histological pattern
• Molecularly, Gleason pattern 3 cells have relatively normal molecular features: no oncogenic pathway activation, no invasion/metastasis gene overexpression
• Most powerful predictor of non-aggressiveness in prostate cancer
• Grade Group 1 carries the best prognosis of all prostate cancers

"For the purposes of this chapter, low-grade cancer refers to Gleason grade group 1, or a Gleason score of 6 (3+3)... During a 2- to 3-year period after biopsy, more than 80% of men's prostate cancer grades remain stable." — Campbell Walsh Wein Urology

No Perineural Invasion — Favorable Sign

Treatment Options for a 76-Year-Old Man with Low-Risk Prostate Cancer

• Tumor behavior (Grade Group 1 = very slow-growing)
• Life expectancy (average life expectancy at 76 is ~10 years)
• Comorbidities (not stated but relevant)
• Patient preference and quality of life

Option 1: Active Surveillance (Preferred for Age ≥75 with Low-Risk Disease)

"The basic concept of active surveillance is to manage patients with low-grade prostate cancer conservatively, reserving treatment for those who are upgraded over time." — Campbell Walsh Wein Urology

• PSA every 3–6 months
• Repeat biopsy at 12–18 months (particularly important given the 4 ASAP cores)
• mpMRI prostate recommended to characterize extent of disease
• Major advantage for a 76-year-old: avoids treatment morbidity (incontinence, erectile dysfunction) for a disease unlikely to cause death within his expected lifespan

Option 2: Radical Prostatectomy (Robotic-Assisted or Open)

• Curative intent — removes the entire prostate
• Generally considered only if life expectancy >10 years and patient fit for surgery
• At age 76, surgical risk and recovery must be carefully weighed
• Complications: urinary incontinence (10–20%), erectile dysfunction (40–60%)
• Less favored in a 76-year-old with Grade Group 1 disease unless patient highly motivated and surgically fit

Option 3: Radiation Therapy (External Beam RT or Brachytherapy)

• Equivalent oncological outcomes to surgery for low-risk disease
• Brachytherapy (radioactive seeds) well-suited for low-risk, organ-confined cancer
• External beam RT with or without androgen deprivation
• Lower surgical risk than prostatectomy — better suited for elderly patients

Option 4: Watchful Waiting (Observation Only)

• Distinguished from active surveillance: no intent to intervene — palliative management only if symptomatic
• Appropriate for men with very limited life expectancy (<5 years) or significant comorbidities
• May be considered if active surveillance monitoring is not feasible

Immediate Next Steps Recommended

1. PSA level — essential for staging (not included in this biopsy report). PSA <10 likely; if >10, changes risk classification
2. Digital rectal examination (DRE) — clinical T-stage needed for NCCN risk stratification
3. Multiparametric MRI (mpMRI) of the prostate — defines extent of disease, identifies potential extraprostatic extension, and guides any repeat biopsy targeting
4. Repeat biopsy in 6–12 months — mandatory given 4 cores of ASAP bilaterally (40% cancer risk per core); targeted MRI-guided biopsy preferred
5. Multidisciplinary discussion involving urology, radiation oncology, and the patient's overall fitness/comorbidity status
6. Shared decision-making with patient and family — at 76, quality of life considerations are paramount

Summary for the Operating Surgeon

Updated Clinical Assessment with New Parameters

Patient: Revabhai Koyabhai Patel | Male, 76 Years

Step 1: PSA Density Calculation

PSAD = 25 ng/mL ÷ 50 g = 0.50 ng/mL/g

Interpretation:

"PSA density, which is total PSA divided by prostate volume, is another PSA-derived metric and provides substantially more predictive information than PSA velocity. Proposed cutoffs for biopsy in the early detection setting have ranged from 0.08 to 0.15 ng/mL²." — Campbell Walsh Wein Urology

Step 2: Revised NCCN Risk Stratification

Final Risk Classification: HIGH RISK

NCCN High Risk criteria: T3a OR Gleason score 8/Grade Group 4 OR PSA >20 ng/mL — Campbell Walsh Wein Urology, Table 153.1

Step 3: Why Is PSA 25 in a Grade Group 1 Cancer Alarming?

Possible Explanations (in order of clinical priority):

"A Gleason score less than or equal to 6 on biopsy corresponds to a Gleason score ≤6 in the radical prostatectomy in about 65% of cases — meaning 35% will be upgraded... Factors associated with upgrading include: increased serum PSA levels." — Campbell Walsh Wein Urology

Step 4: Active Surveillance Criteria — Does This Patient Qualify?

• Gleason score ≤6 ✅
• No more than 2 positive cores ✅
• No core >50% involved ✅ (40% max in core 3)
• PSA density <0.15 ❌ (This patient: 0.50 — over 3× the cut-off)

"The Epstein Criteria... predicts organ-confined tumors... PSA density < 0.15 ng/mL/g... Accuracy of predicting insignificant cancer: 79–83%." — Campbell Walsh Wein Urology

"Clinical parameters such as... higher PSA density (>0.15) place men at increased risk of being reclassified on subsequent biopsy." — Campbell Walsh Wein Urology

Step 5: Mandatory Next Steps Before Any Treatment Decision

1. Multiparametric MRI (mpMRI) of the Prostate — URGENT PRIORITY

• Identify PI-RADS 4–5 lesions not sampled on systematic biopsy
• Guide targeted MRI-fusion biopsy of suspicious areas
• Assess for extraprostatic extension, seminal vesicle invasion, neurovascular bundle involvement
• Define true disease extent before treatment planning

2. MRI-Targeted Repeat Biopsy (Fusion Biopsy)

3. Bone Scan + CT Chest/Abdomen/Pelvis — Staging for Metastases

"High Risk: Bone imaging: recommended. Pelvic ± abdominal imaging: recommended." — NCCN Risk Stratification Table, Campbell Walsh Wein Urology

• Technetium-99m bone scan — assess for skeletal metastases
• CT abdomen/pelvis — assess pelvic lymph nodes
• Consider PSMA PET-CT (superior sensitivity for nodal and bone mets at PSA >20)

4. PSA Fractions (Free:Total PSA Ratio)

• <10%: high probability of cancer (even without biopsy)

• 25%: more likely benign BPH This helps further characterize the excess PSA and refine cancer risk.

Step 6: Treatment Options — Recalibrated for High-Risk Disease

Option A: Radical Prostatectomy (Robotic or Open)

• Potentially curative for organ-confined high-risk disease
• At age 76, surgical fitness must be carefully assessed (cardiac/pulmonary/anesthetic risk)
• Extended pelvic lymph node dissection (ePLND) is mandatory for high-risk disease
• Post-operative adjuvant or salvage radiotherapy may be needed if margins positive or seminal vesicles involved
• Applicable only if staging shows no distant metastases and patient is surgically fit

Option B: External Beam Radiation Therapy (EBRT) + Androgen Deprivation Therapy (ADT)

• Preferred for elderly high-risk patients unfit or unwilling for surgery
• Long-course ADT (18–36 months) combined with dose-escalated EBRT (74–80 Gy)
• Achieves equivalent long-term cancer-specific survival to surgery in many high-risk series
• Better suited for a 76-year-old — avoids general anesthesia, incontinence risk
• ADT side effects (fatigue, hot flushes, loss of libido, osteoporosis, metabolic syndrome) must be counselled

Option C: Brachytherapy ± EBRT ± ADT

• High-dose rate (HDR) or low-dose rate (LDR) brachytherapy combined with EBRT for high-risk disease
• Less suited as monotherapy for high-risk disease — typically used in combination

Option D: Active Surveillance — NOT RECOMMENDED

• PSA density 0.50 disqualifies this patient from all major AS protocols
• High-risk by NCCN criteria mandates staging and likely active treatment

Complete Clinical Summary

Management Recommendation (in order of priority):

1. mpMRI prostate (urgent) → identify missed higher-grade lesions
2. MRI-fusion targeted repeat biopsy → resolve true Gleason grade
3. Bone scan + CT → exclude metastases (mandatory for PSA >20)
4. MDT discussion (urology + radiation oncology + oncology)
5. Treatment: EBRT + long-course ADT is the most appropriate strategy for a 76-year-old with High-Risk prostate cancer — assuming no distant metastases on staging
6. Radical prostatectomy as an alternative only if patient is excellent surgical candidate with no comorbidities and staging is negative

Bottom line: PSA 25 ng/mL with a 50 g prostate (PSAD = 0.50) reclassifies this patient from Low Risk to HIGH RISK. Active surveillance is contraindicated. Urgent staging with mpMRI, bone scan, and CT is required before any definitive treatment, with strong suspicion that targeted biopsy will reveal higher-grade disease than the current Grade Group 1.

Can This Patient Be Treated with Medicine, or Is Surgery Needed?

Direct Answer: Both are valid options — but medicine (radiation + hormones) is likely the better choice for this patient. Surgery alone is insufficient and not routinely recommended as first-line for his risk profile.

Why This Patient Cannot Simply Be "Treated with Medicine Alone" in the Conventional Sense

• Tablets or oral medications alone cannot cure prostate cancer — they can control it, suppress it, or slow it, but they are not curative monotherapy for localized high-risk disease
• Watchful waiting with no active treatment is inappropriate — PSA 25 demands intervention

Option 1: Radiation Therapy + Androgen Deprivation Therapy (ADT) — Recommended for This Patient

A. External Beam Radiation Therapy (EBRT / IMRT)

• High-dose radiation (76–86 Gy) delivered to the prostate in fractionated doses over ~8 weeks
• Destroys cancer cells locally without surgery
• No general anesthesia — suitable for elderly patients
• Whole-pelvis radiation included if lymph node involvement is suspected

"Intermediate- and high-risk prostate cancer is typically treated with IMRT coupled with androgen deprivation therapy for up to 3 years. Low-, intermediate-, and high-risk prostate cancers have cancer survival outcomes after radiation-based therapy similar to those of radical prostatectomy." — Sabiston Textbook of Surgery

B. Androgen Deprivation Therapy (ADT) — The "Medicine" Component

"The use of LHRH agonists — including leuprolide and goserelin, alone or in combination with an antiandrogen (e.g., flutamide, bicalutamide, enzalutamide, or nilutamide) — is the preferred approach." — Katzung's Basic and Clinical Pharmacology, 16th Ed

"Hormonal treatment reduces symptoms — especially bone pain — in 70–80% of patients and may cause a significant reduction in PSA level." — Katzung's Basic and Clinical Pharmacology

Expected Effect of ADT on This Patient's PSA:

• PSA will typically drop from 25 ng/mL to <0.1 ng/mL ("undetectable") within 3–6 months of starting ADT
• This confirms treatment response and testosterone suppression
• PSA is monitored every 3–6 months as a marker of cancer control

Option 2: Radical Prostatectomy (Surgery) — Possible But Not First Choice at Age 76

"Radical prostatectomy can cure some men with high-risk disease features, and the addition of adjuvant therapy may further improve outcomes." — Campbell Walsh Wein Urology

"Advances in delivery of RT and recognition that combined modality treatment (e.g., RT and androgen deprivation) improved outcomes compared with monotherapy have contributed to the migration away from surgery for high-risk tumors." — Campbell Walsh Wein Urology

What About Medicine Alone (ADT Without Radiation)?

• As neoadjuvant (before radiation — to shrink the tumor)
• As concurrent (during radiation — to sensitize cells)
• As adjuvant (after radiation — to eliminate micrometastases)
• In patients too frail for any local therapy — as palliative/disease control only

Summary: What Should Be Done for This Patient

In Simple Terms:

This patient needs both "medicine" AND a local treatment — but the best "medicine" for him is Radiation + Hormone Injections (ADT), not tablets alone. Surgery is possible but not the preferred option at 76 years of age with high-risk disease. Do not use hormones alone without radiation — that is not curative.